Aduro Biotech (Aduro Biotech) Cash Flow from Financing : $0.26 Mil (TTM As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aduro Biotech Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jun. 2020, Aduro Biotech paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Aduro Biotech spent $0.00 Mil on financial activities for the three months ended in Jun. 2020.

Aduro Biotech Cash Flow from Financing Historical Data

The historical data trend for Aduro Biotech's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aduro Biotech Cash Flow from Financing Chart

Aduro Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash Flow from Financing

Get a 7-Day Free Trial

174.18

43.09

82.05

-1.50

0.74

Aduro Biotech Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Cash Flow from Financing	Get a 7-Day Free Trial															0.35	0.09	0.05	0.08	0.04

Aduro Biotech Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Aduro Biotech's Cash from Financing for the fiscal year that ended in Dec. 2019 is calculated as:

	Cash Flow from Financing		(A: Dec. 2019 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Aduro Biotech's Cash from Financing for the quarter that ended in Jun. 2020 is:

	Cash Flow from Financing		(Q: Jun. 2020 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26 Mil.

Aduro Biotech (NAS:ADRO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Aduro Biotech's issuance of stock for the three months ended in Jun. 2020 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Aduro Biotech's repurchase of stock for the three months ended in Jun. 2020 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Aduro Biotech's net issuance of debt for the three months ended in Jun. 2020 was $0.00 Mil. Aduro Biotech received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Aduro Biotech's net issuance of preferred for the three months ended in Jun. 2020 was $0.00 Mil. Aduro Biotech paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Aduro Biotech's cash flow for dividends for the three months ended in Jun. 2020 was $0.00 Mil. Aduro Biotech received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Aduro Biotech's other financing for the three months ended in Jun. 2020 was $0.00 Mil. Aduro Biotech received $0.00 Mil on other financial activities.

Aduro Biotech Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Aduro Biotech's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Aduro Biotech (Aduro Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aduro Biotech Inc (NAS:ADRO) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 Heinz Avenue, Berkeley, CA, USA, 94710

Website

https://www.aduro.com

Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.

Executives

Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
William Mariner Greenman	director	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Ross Haghighat	director	C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Tom Frohlich	officer: Chief Business Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Dobmeier	director, officer: President, CEO	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Andrew James King	officer: Head of Renal Discovery	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Alan Glicklich	officer: Chief Medical Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Celeste Ferber	officer: SVP, GC and Secretary	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Blaine Templeman	officer: Chief Legal Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710